scispace - formally typeset
Open AccessJournal ArticleDOI

Insights into the Recent 2019 Novel Coronavirus (SARS-CoV-2) in Light of Past Human Coronavirus Outbreaks

Reads0
Chats0
TLDR
Wang et al. as mentioned in this paper discuss structure, genome organization, entry of CoVs into target cells, and provide insights into past and present outbreaks of human CoV outbreaks and develop efficient prevention and treatment strategies to deal with this continuous threat.
Abstract
Coronaviruses (CoVs) are RNA viruses that have become a major public health concern since the Severe Acute Respiratory Syndrome-CoV (SARS-CoV) outbreak in 2002. The continuous evolution of coronaviruses was further highlighted with the emergence of the Middle East Respiratory Syndrome-CoV (MERS-CoV) outbreak in 2012. Currently, the world is concerned about the 2019 novel CoV (SARS-CoV-2) that was initially identified in the city of Wuhan, China in December 2019. Patients presented with severe viral pneumonia and respiratory illness. The number of cases has been mounting since then. As of late February 2020, tens of thousands of cases and several thousand deaths have been reported in China alone, in addition to thousands of cases in other countries. Although the fatality rate of SARS-CoV-2 is currently lower than SARS-CoV, the virus seems to be highly contagious based on the number of infected cases to date. In this review, we discuss structure, genome organization, entry of CoVs into target cells, and provide insights into past and present outbreaks. The future of human CoV outbreaks will not only depend on how the viruses will evolve, but will also depend on how we develop efficient prevention and treatment strategies to deal with this continuous threat.

read more

Citations
More filters
Journal ArticleDOI

Achieving a Covid-19 Free Country: Citizens Preventive Measures and Communication Pathways.

TL;DR: This study investigates whether Greek citizens take the necessary precautions to prevent developing the COVID-19 disease, and it segments them based on homogenous behavior groups, and provides communication techniques that should be implemented, targeting each citizen segment for a long-term CO VID-19 free country.
Journal ArticleDOI

Current emerging SARS-CoV-2 pandemic: Potential direct/indirect negative impacts of virus persistence and related therapeutic drugs on the aquatic compartments.

TL;DR: The present detailed report of up-to-date knowledge on this topic can provide a useful source for further studies focusing on more deepened investigations of SARS-CoV-2 behaviour in the environment.
Journal ArticleDOI

Neurological Complications of COVID-19: Underlying Mechanisms and Management.

TL;DR: In this paper, the authors discuss the prevalence, pathogenesis, and mechanisms of these neurological sequelae that are secondary to SARS-CoV-2 infection and aim to update neurologists and healthcare workers on the possible neurological complications associated with COVID-19 and the management of these disease conditions.
Journal ArticleDOI

SARS-CoV-2: Repurposed drugs and novel therapeutic approaches—insights into chemical structure—biological activity and toxicological screening

TL;DR: A thorough analysis of repurposed drug admitted for compassionate use from a chemical structure—biological activity perspective highlighting the ADME ( absorption, distribution, metabolism, and excretion) properties and the toxicophore groups linked to potential adverse effects is presented.
References
More filters
Journal ArticleDOI

A Novel Coronavirus from Patients with Pneumonia in China, 2019.

TL;DR: Human airway epithelial cells were used to isolate a novel coronavirus, named 2019-nCoV, which formed a clade within the subgenus sarbecovirus, Orthocoronavirinae subfamily, which is the seventh member of the family of coronaviruses that infect humans.
Journal ArticleDOI

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation.

TL;DR: The authors show that this protein binds at least 10 times more tightly than the corresponding spike protein of severe acute respiratory syndrome (SARS)–CoV to their common host cell receptor, and test several published SARS-CoV RBD-specific monoclonal antibodies found that they do not have appreciable binding to 2019-nCoV S, suggesting that antibody cross-reactivity may be limited between the two RBDs.
Related Papers (5)